Compare Raymond James Financial, Inc. (RJF) vs Twist Bioscience Corp (TWST) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Raymond James Financial, Inc. vs Twist Bioscience Corp — how do they compare? Raymond James Financial, Inc. trades at $158.28 (market cap $30.51B), while Twist Bioscience Corp trades at $159.78 (market cap $10.08B). The key difference: Raymond James Financial, Inc. is far larger — about 3× Twist Bioscience Corp's market cap, and Raymond James Financial, Inc. pays a 1.36% dividend while Twist Bioscience Corp pays none. Which is the better fit depends on your goals — on Pluang, investors hold Raymond James Financial, Inc. for 75 Days and Twist Bioscience Corp for 27 Days on average.
| RJF | TWST | |
|---|---|---|
Market Cap | $30.51B | $10.08B |
Volume | 1,206,253 | 4,229,037 |
Sector | Financials | Health |
52-Week High | $181.18 | $205.00 |
52-Week Low | $140.89 | $25.45 |
Typical Hold Time | 75 Days | 27 Days |
Enterprise Value | $24.37B | $10.01B |
Dividend Yield | 1.36% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Raymond James Financial (RJF) trades at $158.60, up 0.83% with consistent earnings beats in recent quarters. The stock shows bearish technical signals but maintains strong fundamentals with 15.37% net margins and 18.48% ROE. Recent Q3 2026 results showed record revenues of $3.93 billion, beating expectations. The company continues dividend payments with a $0.54 quarterly payout declared for October 2026.
RJF presents a mixed outlook with strong fundamental performance offset by technical weakness. The 16% upside to consensus price target of $184.00 offers potential, but investors face headwinds from rising expenses and market volatility. The absence of sell ratings and consistent institutional interest supports the investment case, though technical indicators suggest near-term caution.
Twist Bioscience (TWST) trades at $152.05, down 2.31% today but remains near recent highs following a significant rally driven by AI partnerships and strong sector interest. The company shows improving revenue growth ($377M in 2025) but continues to post substantial losses (-$78M net income). Technical indicators show mixed signals with bullish overall sentiment but bearish moving averages, while analyst consensus remains positive with 73% buy ratings.
TWST presents a high-risk, high-reward opportunity with strong growth potential through AI-driven drug discovery partnerships but faces significant execution risks amid persistent profitability challenges. The stock's valuation appears stretched given current fundamentals, requiring successful commercialization of pipeline assets to justify premium multiples.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Raymond James Financial, Inc.
Raymond James Financial is a financial holding company whose major operations include wealth management, investment banking, asset management, and commercial banking. The company has more than 14,000 employees and supports more than 5,000 independent contractor financial advisors across the United States, Canada, and the United Kingdom. Approximately 90% of the company's revenue is from the U.S. and 70% is from the company's wealth-management segment.
Read more on RJF →About Twist Bioscience Corp
Twist Bioscience Corp is a synthetic biology company. It develops a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's DNA synthesis platform utilizes a proprietary semiconductor-based synthetic DNA manufacturing process that synthesizes DNA on silicon instead of on traditional well plastic plates to enable the production of high-quality synthetic DNA faster and affordable as well as overcomes inefficiencies. Powering cost-effective, rapid high-throughput synthesis, it enables researchers to rapidly realize opportunities ahead. Geographically, it derives a majority of revenue from the United States.
Read more on TWST →
